Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in TEM.
← Back to Free Index

TEM

Analysis as of: 2026-05-14
Tempus AI, Inc.
Tempus provides genomic testing, clinical workflow software, and governed multimodal data products to clinicians, health systems, researchers, and life sciences companies.
ai biotech enterprise healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Governed oncology data can outgrow lab economics
The core question is whether testing volume keeps feeding a higher-value data and workflow business fast enough to escape a plain diagnostics valuation. Recent financing and pharma traction help, but reimbursement proof still decides how much of the upside becomes durable equity value.

Analysis

Thesis
Tempus can compound at a bull-case rate if it keeps turning each diagnostic interaction into governed data, workflow, and life-sciences revenue, while the May 2026 refinancing gives it more time for MRD reimbursement and assay approvals to mature. The upside is mostly mix shift and scale, not a heroic rerating.
Last Economy Alignment
Tempus benefits as AI makes analysis cheap because it controls scarcer assets: rights-cleared clinical data, trusted workflow, and regulated deployment. It is helped by the Last Economy, but reimbursement and approval gates keep it below the top tier.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.7x (from 5 most recent analyses)
Reasoning
This case does not require a dramatic rerating. If diagnostics keeps feeding higher-value data, workflow, and pharma revenue, Tempus can be valued more like a healthcare operating layer than a stand-alone lab. The stock can work through strong revenue compounding plus some quality-of-revenue improvement, while reimbursement and financing risk gradually fade.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is economic conversion, not product novelty. Tempus must prove that fast diagnostics growth really turns into durable, higher-value data and workflow economics before reimbursement delays, regulatory gates, or competitive workflow capture keep investors valuing it mostly like a lab.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.59
They control permissioned cancer data and physician workflow points that get more valuable as AI makes analysis cheaper. The risk is that reimbursement, regulation, or EHR and lab rivals keep them looking like a smart lab instead of a true healthcare operating layer.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$72.46
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case